MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/circinterventions.118.007541

Медицинская библиотека · Circulation. Cardiovascular interventions · 2019

Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.

Palmerini Tullio, Bruno Antonio G, Gilard Martine, Morice Marie-Claude, Valgimigli Marco, Montalescot Gilles, Collet Jean-Philippe, Della Riva Diego, Bacchi-Reggiani Maria Letizia, Steg Philippe Gabriel, Diallo Abdourahmane, Vicaut Eric, Helft Gerard, Nakamura Masato, Généreux Philippe, Vahl Torsten P, Stone Gregg W

СтатьяМетаанализПеревод пока не подготовлен

Аннотация

BACKGROUND

We sought to determine whether the risks and benefits of prolonging dual-antiplatelet therapy (DAPT) beyond 1 year after drug-eluting stent implantation depend on clinical presentation in a meta-analysis of randomized controlled trials.

METHODS AND

RESULTS

Randomized controlled trials comparing ≤1- versus >1-year DAPT after drug-eluting stent placement were searched through MEDLINE, EMBASE, Cochrane databases, and proceedings of international meetings. The primary efficacy end point was myocardial infarction, whereas the primary safety end point was major bleeding. Net clinical benefit was defined as the composite of myocardial infarction or major bleeding. Outcomes were analyzed according to patient presentation with stable ischemic heart disease versus acute coronary syndromes. The meta-analysis included 6 trials with a total of 21 457 patients, including 14 132 with stable ischemic heart disease and 7325 with acute coronary syndrome. After a median follow-up of 19.5 months, ≤1-year DAPT was associated with higher rates of myocardial infarction compared with >1-year DAPT (hazard ratio [HR], 1.63; 95% CI, 1.37-1.95), with no interaction apparent between treatment effect and clinical presentation. Shorter DAPT was associated with reduced rates of major bleeding compared with longer DAPT (HR, 0.64; 95% CI, 0.42-0.99) with no significant interaction between treatment effect and clinical presentation. However, a net clinical benefit of >1-year DAPT was present in patients with acute coronary syndrome (HR of shorter versus longer DAPT, 1.59; 95% CI, 1.24-2.02) but not in those with stable ischemic heart disease (HR, 1.15; 95% CI, 0.89-1.51; Pinteraction=0.04). Shorter DAPT was also associated with lower rates of noncardiac mortality compared with longer DAPT (HR, 0.71; 95% CI, 0.52-0.96), with no significant interaction between treatment effect and clinical presentation ( Pinteraction=0.12).

CONCLUSIONS

Compared with ≤1-year DAPT, >1-year DAPT reduces the risk of myocardial infarction but increases the risk of major bleeding and noncardiac mortality. A net clinical benefit of extended DAPT was apparent for patients with acute coronary syndrome but not for those with stable ischemic heart disease.

Для цитирования: Palmerini Tullio, Bruno Antonio G, Gilard Martine, Morice Marie-Claude, Valgimigli Marco, Montalescot Gilles, Collet Jean-Philippe, Della Riva Diego, Bacchi-Reggiani Maria Letizia, Steg Philippe Gabriel, Diallo Abdourahmane, Vicaut Eric, Helft Gerard, Nakamura Masato, Généreux Philippe, Vahl Torsten P, Stone Gregg W. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.. Circulation. Cardiovascular interventions. 2019. DOI: 10.1161/circinterventions.118.007541.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.